Fuller & Thaler Asset Management, Inc. Exelixis, Inc. Transaction History
Fuller & Thaler Asset Management, Inc.
- $25 Billion
- Q3 2024
A detailed history of Fuller & Thaler Asset Management, Inc. transactions in Exelixis, Inc. stock. As of the latest transaction made, Fuller & Thaler Asset Management, Inc. holds 6,922,628 shares of EXEL stock, worth $244 Million. This represents 0.72% of its overall portfolio holdings.
Number of Shares
6,922,628
Previous 2,221,911
211.56%
Holding current value
$244 Million
Previous $49.9 Million
259.82%
% of portfolio
0.72%
Previous 0.22%
Shares
23 transactions
Others Institutions Holding EXEL
# of Institutions
503Shares Held
244MCall Options Held
2.54MPut Options Held
2.29M-
Black Rock Inc. New York, NY33.5MShares$1.18 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA29.3MShares$1.03 Billion0.01% of portfolio
-
Farallon Capital Management LLC San Francisco, CA25.4MShares$896 Million3.31% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny15.4MShares$542 Million0.63% of portfolio
-
State Street Corp Boston, MA11.4MShares$404 Million0.01% of portfolio
About EXELIXIS, INC.
- Ticker EXEL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 321,832,000
- Market Cap $11.3B
- Description
- Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...